Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Colin Baigent,Lisa Blackwell,Rory Collins,Jonathan Emberson,Jon Godwin,Richard Peto,Julie E. Buring,Charles H. Hennekens,Patricia M. Kearney,Tom W. Meade,Carlo Patrono,Maria Carla Roncaglioni,Alberto Zanchetti +12 more
Reads0
Chats0
TLDR
In primary prevention without previous disease, aspirin is of uncertain net value as the reduction in occlusive events needs to be weighed against any increase in major bleeds.About:
This article is published in The Lancet.The article was published on 2009-05-30 and is currently open access. It has received 2954 citations till now. The article focuses on the topics: Stroke & Aspirin.read more
Citations
More filters
Journal ArticleDOI
Evolving management of symptomatic chronic subdural hematoma: experience of a single institution and review of the literature
TL;DR: Despite decreasing LOSs as treatment for c SDH evolved from BHs to SEPS, the LOS for a cSDH is still longer than that of a patient undergoing craniotomy for brain tumor.
Journal ArticleDOI
HIV and Africa's elderly: the problems and possibilities
TL;DR: The epidemiological data on HIV prevalence among older Africans, and progress and barriers to accessing treatment and care are summarized, with a focus on cardiovascular disease, neuropsychiatric conditions, oncologic illness, and musculoskeletal morbidity.
Journal ArticleDOI
Low-dose aspirin use and recurrent gout attacks
TL;DR: In this article, the authors examined the association between cardioprotective use of low-dose aspirin and the risk of recurrent gout attacks among gout patients, and found that the use on two consecutive days is associated with an increased risk of gout attack.
Journal ArticleDOI
Evaluation and Management of Patients With Stable Angina: Beyond the Ischemia Paradigm: JACC State-of-the-Art Review.
Richard A. Ferraro,Jacqueline Latina,Abdulhamied Alfaddagh,Erin D. Michos,Michael J. Blaha,Steven R. Jones,Garima Sharma,Jeffrey C. Trost,William E. Boden,William S. Weintraub,Joao A.C. Lima,Roger S. Blumenthal,Valentin Fuster,Armin Arbab-Zadeh +13 more
TL;DR: The scientific evidence in support of medical therapy and revascularization for the management of patients with stable coronary heart disease is reviewed and implications for the evaluation of patientswith stable angina and public policy are discussed.
Journal ArticleDOI
Coronary artery disease: Risk stratification and patient selection for more aggressive secondary prevention:
TL;DR: Patients aged over 65 years of age and those with a history of intra-cranial haemorrhage are not eligible for intensification of anti-thrombotic therapy, but patients with prior or recurrent myocardial infarction may benefit from this strategy, especially if they are current smokers or have diabetes mellitus.
References
More filters
Journal ArticleDOI
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
Colin Baigent,Anthony C Keech,Patricia M. Kearney,L Blackwell,Georgina Buck,Christine Pollicino,Adrienne Kirby,T Sourjina,Richard Peto,Rory Collins,R. J. Simes +10 more
TL;DR: Statin therapy can safely reduce the 5-year incidence of major coronary events, coronary revascularisation, and stroke by about one fifth per mmol/L reduction in LDL cholesterol, largely irrespective of the initial lipid profile or other presenting characteristics.
Journal ArticleDOI
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
TL;DR: Aspirin (or another oral antiplatelet drug) is protective in most types of patient at increased risk of occlusive vascular events, including those with an acute myocardial infarction or ischaemic stroke, unstable or stable angina, previous myocardian infarctions, stroke or cerebral ischaemia, peripheral arterial disease, or atrial fibrillation.
Journal ArticleDOI
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial
Lennart Hansson,Alberto Zanchetti,S. George Carruthers,Björn Dahlöf,Dag Elmfeldt,Stevo Julius,Joël Ménard,Karl Heinz Rahn,Hans Wedel,Sten Westerling +9 more
TL;DR: Intensive lowering of blood pressure in patients with hypertension was associated with a low rate of cardiovascular events and the potential benefit of a low dose of acetylsalicylic acid in the treatment of hypertension was assessed.
Journal ArticleDOI
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
Paul M. Ridker,Eleanor Danielson,Jacques Genest,Antonio M. Gotto,Wolfgang Koenig,Peter Libby,Alberto J. Lorenzatti,Jean G. MacFadyen,Børge G. Nordestgaard,James Shepherd,James T. Willerson,Robert J. Glynn +11 more
TL;DR: In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events.
Journal ArticleDOI
Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies
Gary Whitlock,Sarah Lewington,Paul Sherliker,Robert Clarke,Jonathan Emberson,Jim Halsey,Nawab Qizilbash,Rory Collins,Richard Peto +8 more
TL;DR: Below the range 22.5-25 kg/m(2), BMI was associated inversely with overall mortality, mainly because of strong inverse associations with respiratory disease and lung cancer, despite cigarette consumption per smoker varying little with BMI.